Key Highlights

  • Pre-market price of USD 0.943 on November 4, 2026, up USD 0.1000 from the Tuesday close
  • Robocath's first-in-human coronary study reported 100% clinical success across 20 of 20 patients
  • Second quarter 2026 Revenue was USD 7.7 million, compared with USD 8.8 million a year earlier
  • Cash was USD 10.5 million with no Debt at June 30, 2026
  • Third quarter results are scheduled for November 10, 2026 after the market close

What Lifted Stereotaxis Before the Open (up USD 0.1000, 11.86%)

Stereotaxis (NYSEAMERICAN:STXS) climbed 11.86% to USD 0.943 in pre-market trading on November 4, 2026, a gain of USD 0.1000 from the Tuesday, November 3 close of about USD 0.843 (calculated). The move came after a company press release dated November 2, 2026 covering first-in-human results for the next generation robotic system of its Robocath subsidiary.

The data were presented on November 1, 2026 at a cardiology conference in San Diego. The company has not linked the share move to the release, so the timing is an inference rather than a confirmed cause.

Robocath Study Details

The prospective pilot study enrolled 20 patients undergoing percutaneous coronary intervention at a cardiology centre in Saint-Denis, France. The system builds on the first generation R-One and can handle up to five interventional devices at once.

Clinical success, defined by the study's minimal residual stenosis criterion after the procedure, was 100% (20 of 20). Technical success was 95%, and all procedures but one were completed robotically without conversion to manual. There were no intra-procedural vascular complications, major adverse events or device-related adverse events through 30-day follow-up, and operators reported no fluoroscopy exposure.

The lesions treated included A/B1, B2 and C types, among them tortuous distal vasculature. A manuscript has been submitted and is under review. Chairman and chief executive David Fischel said the results "support our confidence in our innovation strategy." The sample is small and the data preliminary, with no comparator group or confidence intervals disclosed.

Business Background and Recent Results

Stereotaxis describes itself as a pioneer in surgical robotics for minimally invasive endovascular intervention, with its technology used to treat over 150,000 patients. It has completed the Robocath acquisition, which was announced at up to USD 45 million.

In its release dated August 11, 2026, second quarter revenue was USD 7.7 million, down from USD 8.8 million, as systems revenue fell to USD 1.5 million from USD 3.0 million with no robotic system delivered. Recurring Revenue rose to USD 6.2 million from USD 5.8 million, and gross Margin was 58%. The net loss widened to USD 4.5 million from USD 3.8 million, or USD 0.05 per share, and free Cash Flow was negative USD 3.7 million.

Revenue from the company's MAGiC robotic catheters exceeded USD 1 million in the quarter, up 270% sequentially, and the first US hospital purchase of a GenesisX system is due to be installed this fall.

Balance Sheet, Guidance and Risks

Cash was USD 10.5 million with no debt at June 30, 2026, and stockholders' Equity was USD 12.2 million. The company guided to recurring revenue of about USD 7 million in the third quarter and USD 8 million in the fourth, with systems revenue of about USD 3 million in each, and expects cash flow profitability in the first half of 2027.

At about USD 0.94 the stock is a penny stock, carrying volatility, thin Liquidity and potential dilution risk. Purchase orders are subject to contingencies and can be delayed or cancelled, and the company continues to post net losses.

What to Watch Next

Third quarter 2026 results are due after the close on November 10, 2026, with a call at 4:30 p.m. Eastern. Investors will look at whether recurring revenue approaches the USD 7 million guidance and at the pace of GenesisX installations.